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maviruses, E6AP targets the tumor suppressor p53 for degradation, thereby contributing to
carcinogenesis. Moreover, E6 acts as a potent activator of E6AP by a yet unknown
mechanism. However, structural information explaining how the E6AP-E6-p53 enzyme-
substrate complex is assembled, and how E6 stimulates E6AP, is largely missing. Here, we
develop and apply different crosslinking mass spectrometry-based approaches to study the
E6AP-E6-p53 interplay. We show that binding of E6 induces conformational rearrangements
in E6AP, thereby positioning E6 and p53 in the immediate vicinity of the catalytic center of
E6AP. Our data provide structural and functional insights into the dynamics of the full-length
E6AP-E6-p53 enzyme-substrate complex, demonstrating how E6 can stimulate the ubiquitin
ligase activity of E6AP while facilitating ubiquitin transfer from E6AP onto p53.
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In eukaryotes, covalent modiﬁcation of proteins by ubiquitin(ubiquitylation) plays a pivotal role in the regulation of manykey cellular processes, including cell cycle, DNA metabolism
(e.g., DNA repair), and various signal transduction pathways1–3.
The speciﬁcity of the ubiquitin–conjugation system is mainly
ensured by E3 ubiquitin ligases, which mediate the recognition of
target proteins. Based on the presence of distinct domains and
their mode of action, E3 ligases have been grouped into three
families, RING/RING-like E3s, RING-between-RING (RBR) E3s,
and HECT E3s4,5. In a simpliﬁed view, all E3s have at least two
binding sites, one for substrate proteins and one for cognate E2
ubiquitin-conjugating enzymes. However, while RBR E3s and
HECT E3s form a covalent intermediate with ubiquitin and
transfer it to their targets, RING/RING-like E3s function mainly
as adaptors facilitating the direct transfer of ubiquitin from the E2
to the substrate.
Deregulation of ubiquitylation—at the substrate level or at the
level of the conjugation machinery—has been causally involved in
the development of human disease, including cancer, neurological
disorders, and viral infections1,6–9. A prominent example is
provided by E6AP, the founding member of the HECT (homo-
logous to E6AP C terminus) E3 family10,11. E6AP was originally
identiﬁed as a cellular interaction partner of the E6 oncoprotein
of so-called high-risk human papillomaviruses (HPVs) such as
HPV-16, which cause anogenital cancers, most notably cancer of
the uterine cervix12,13. In complex with E6, E6AP targets the
tumor suppressor p53 and other proteins—which in the absence
of E6 are not targeted by E6AP—for ubiquitylation and degra-
dation by the 26S proteasome, thereby contributing to HPV-
induced cervical carcinogenesis14–16. E6AP is encoded by the
UBE3A gene, which is located on chromosome 15q11-13. In 1997,
it was shown that genetic alterations of the UBE3A gene, resulting
in loss of E6AP expression or in the expression of E6AP variants
with compromised E3 activity, are the cause of the Angelman
syndrome (AS), a neurodevelopmental disorder17–20. However,
although several potential substrate proteins of E6AP have been
reported, including HHR23A and HHR23B, AIB1, PML, alpha-
Synuclein, Ring1B, and Arc21–27, the pathophysiologic relevance
of these interactions remains mostly unclear. More recently, it
was reported that ampliﬁcation of the chromosomal region
containing the UBE3A gene is found in individuals with Dup15q
syndrome, an autism spectrum disorder28,29. Although ﬁnal proof
that ampliﬁcation of the UBE3A gene underlies the Dup15q
syndrome is missing, experiments in mice and fruit ﬂies support
the notion that increased E6AP levels result in autistic
phenotypes30,31.
The ﬁndings that alteration of the substrate spectrum (cer-
vical cancer), loss of E3 function (AS), and increased E3
function (Dup15q) of E6AP contribute to the development of
distinct disorders indicate that expression and/or E3 activity of
E6AP have to be tightly controlled. Indeed, in certain brain
areas the paternal allele is silenced by a UBE3A antisense
transcript (i.e. in these areas, E6AP is mainly expressed from
the maternal allele and genetic alterations of the maternal allele
are responsible for AS development)32, and recent evidence
indicates that the phosphorylation status of T485 (numbering
according to isoform 1 of human E6AP33) affects E6AP
activity34. In addition, there is strong evidence that the E3
activity of E6AP can be activated by interacting proteins.
HERC2, a giant HECT E3, binds to a region within the N-
terminal 200 amino acid residues of E6AP and somehow sti-
mulates the E3 activity of E6AP35. Mutations in the HERC2
gene, which result in increased degradation of HERC2 and,
thus, in decreased expression levels, have been etiologically
associated with an AS-like syndrome pointing to the impor-
tance of the HERC2-E6AP interaction36. Similarly, the E6
oncoprotein not only alters the substrate spectrum of E6AP, but
also acts as a potent activator of E6AP by a yet unknown
mechanism37.
The data obtained with HERC2 and the E6 oncoprotein35,37
suggest that E6AP exists in at least two inter-converting con-
formational states of higher and lower activity. However, while
the structure of the catalytic HECT domain was solved almost
two decades ago38, there is little structural information con-
cerning full-length E6AP or for the N-terminal part of E6AP,
with the exception of the AZUL domain39 and the E6 binding
region40.
Similarly, the crystal structure of E6 bound to an E6AP-derived
peptide of 12 amino acids containing the LQELL motif and to the
DNA binding domain of p53 was recently solved41. While
revealing the role of the E6-binding region of E6AP in assembling
the E6–p53 interaction, the structure did not provide any insight
into how full-length E6AP is oriented towards E6 and p53 in the
E6AP–E6–p53 complex and how the E3 activity of E6AP
becomes stimulated by interaction with E6.
Yet, this information is essential for a molecular understanding
of how interaction partners regulate E6AP activity. Thus, in this
study, we developed and applied different approaches in struc-
tural mass spectrometry (MS), in particular, chemical cross-
linking coupled to MS (XL-MS) to study the effect of the E6
oncoprotein on E6AP conformation. The general approach of
XL-MS is to introduce covalent bonds between proximal func-
tional groups of proteins or protein complexes by crosslinking
reagents. The actual crosslinking sites are subsequently identiﬁed
by MS and reﬂect the spatial proximity of regions within a given
protein (intralinks) or of subunits in a protein complex (inter-
links) (for recent reviews, see refs. 42,43). Thereby, XL-MS pro-
vides a wealth of information on the connectivity, interaction,
and relative orientation of regions within a protein and of sub-
units within a complex, and also contains spatial information in
itself, though at a relatively low resolution.
Using qualitative and quantitative XL-MS approaches, we show
that binding of the E6 oncoprotein induces conformational
changes within full-length E6AP. In addition, we provide evi-
dence that E6 does not only contact the originally identiﬁed E6
binding site of E6AP, but also comes into close proximity to the
catalytic HECT domain and positions the HECT domain next to
its substrate p53. Taken together, our data provide molecular and
structural insights into how the E6 oncoprotein stimulates the E3
activity of E6AP as well as into the full-length E6AP–E6–p53
enzyme–substrate complex.
Results
Binding of E6 induces conformational rearrangement of E6AP.
Even though reasonable amounts of highly puriﬁed E6AP can be
generated, attempts to obtain high-resolution structures of full-
length E6AP, by ourselves and other groups, have so far been
unsuccessful for unknown reasons. Therefore, XL-MS was
applied as an alternative method to obtain insight into protein
structure and in particular into structural rearrangements
induced by an interacting partner42–44. We applied isotopically
labeled disuccinimidyl suberate (DSS) to crosslink highly puriﬁed
E6AP (Supplementary Figure 1) and determined the crosslinking
pattern within full-length E6AP (for a general overview of the
susceptibility of lysine residues to crosslinking in this study, see
Supplementary Figure 2). We identiﬁed 145 unique lysine–lysine
contact sites (uxIDs) within full-length E6AP, corresponding to
396 unique crosslinks that were identiﬁed in total over three
biological replicates (Supplementary Data 1). Figure 1a shows the
overall distribution of high-conﬁdence crosslinks that were
reproducibly and consistently identiﬁed between different
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biological replicates. Crosslinks were identiﬁed over the entire
length of E6AP, encompassing all known functional regions, i.e.,
the AZUL and HECT domains and the HERC2 and E6 binding
sites. We next repeated the experiment in the presence of the
HPV-16 E6 oncoprotein (E6; note that a GST-E6 fusion protein
was employed), identifying 146 unique uxIDs, corresponding to
408 unique crosslinks that were identiﬁed in total over three
biological replicates (Supplementary Data 2). Remarkably, in
addition to the expected interlinks between E6AP and E6, the
presence of E6 had a noticeable effect on the crosslinking pattern
within E6AP itself, leading to diminished crosslinking within the
central region of the protein (i.e., the region of E6AP between the
AZUL and the HECT domain) (Fig. 1b). To corroborate that
changes in the crosslinking pattern were caused by interaction
between E6AP and E6, we repeated the experiment using the
L50E mutant of E6 (E6_L50E; a GST fusion protein was
employed). E6_L50E binds only weakly to E6AP, if at all40, and
consequently does not stimulate the E3 activity of E6AP, as
demonstrated by its inability to rescue E6AP autoubiquitylation
in the presence of the hydrophobic patch mutant UbLIA (Sup-
plementary Figure 3)37. In the presence of E6_L50E, we identiﬁed
131 unique lysine–lysine contact sites, which correspond to 325
unique crosslinks identiﬁed in total over three biological repli-
cates (Supplementary Data 3; for a direct comparison of all
crosslinked peptides under the various conditions see Supple-
mentary Data 4). Importantly, interlinks between E6AP and the
E6 mutant were almost completely absent, supporting previous
ﬁndings that the ability of the mutant to bind E6AP is impaired40
and demonstrating the veracity of our approach. Moreover,
unlike wild-type E6, E6_L50E had little effect on the crosslinking
pattern within E6AP itself (Fig. 1c). Taken together, the distinct
crosslinking patterns obtained suggest that E6AP undergoes a
structural rearrangement upon binding of E6.
The above ﬁndings are in line with our recent experiments
showing that the E6 oncoprotein acts as a potent activator of the
E3 function of E6AP37 in addition to affecting the substrate
spectrum of E6AP. In fact, our initial crosslinking measurements
are consistent with E6 stabilizing a high-activity conformation of
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Fig. 1 Binding of E6 induces a conformational rearrangement of E6AP. Pattern of intralink distribution within E6AP as determined by XL-MS a in the
absence of the HPV E6 oncoprotein, b with wild-type (wt) E6, and c with the E6_L50E mutant, which does not bind to E6AP. Intralinks are shown in dark
blue and interlinks in dark green; lysine residues are shown in black. The catalytic cysteine residue of E6AP at position 820 is indicated in red. The AZUL
domain, HERC2 and E6 binding sites, and the HECT domain are indicated in pastel green, sulfur yellow and sand yellow, respectively. Regions in E6
representing zinc ﬁnger motifs are colored in pastel turquoise and the PDZ binding domain is colored in mint turquoise. d Changes in crosslink abundance
for each unique crosslinking site with E6AP upon binding of wild-type E6 were used to calibrate and normalize the quantitative XL-MS (q-XL-MS) data.
Changes are expressed as fold change (log2 ratio of abundance of E6AP in the presence of E6 versus abundance of E6AP alone). The horizontal red line
indicates the signiﬁcance threshold (fold change: log2 ratio≤ ±1.5). Changes in monolinks are shown in blue and signiﬁcantly changed intralinks within
E6AP are shown in green (relative increase upon binding of E6) and red (relative decrease upon binding of E6), respectively. The p values for each
quantiﬁed link are indicated. e Applying q-XL-MS to recombinantly expressed E6AP in the presence or absence of wild-type E6 identiﬁes numerous high-
conﬁdence crosslinks. Only crosslinks that could be reproducibly quantiﬁed from the pool of identiﬁed high-conﬁdence crosslinks in both samples (with and
without E6) (n= 3, each sample analyzed additionally as technical duplicate) and consistently over 3 different biological replicates are shown (violation=
0; p value≤ 0.01 (two-sided t-test)). Depicted in green are crosslinks that were found to be signiﬁcantly upregulated upon binding of E6, while
downregulated links are shown in red (deﬁned as a log2 change of≥ ±1.5). Crosslinks with no signiﬁcant change are depicted in gray while links that could
not be reliably quantiﬁed are show with a dashed line in light gray. f Quantiﬁcation of the change in abundance of identiﬁed intralinks within E6AP, when
incubated with the binding-deﬁcient E6_L50E mutant vs. E6AP alone, reveals no signiﬁcant up- or downregulated links. For monolinks, see Supplementary
Figure 5
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E6AP. To dissect the structural basis of this reorganization in
more detail, we next employed differential or quantitative XL-MS
(qXL-MS), whereby identiﬁed crosslinks are quantiﬁed via their
MS1 or MS2 intensities43. This technique is a recent
innovation43,45 that is proving to be valuable for analyzing
protein conformations under different conditions44. In order to
normalize the data and also to identify the subset of signiﬁcantly
changed crosslinks, we plotted the quantitative change in the
abundance of monolinks within E6AP in the absence and
presence of E6 (Fig. 1d), reasoning that monolink formation is
dictated primarily by accessibility of a lysine residue and its local
environment (e.g., surrounding amino acid composition, second-
ary structure etc.) and therefore only on rare occasions, if at all,
inﬂuenced by conformational dynamics of the protein. Doing
this, we identiﬁed the vast majority of changes in monolink
abundances ﬂuctuating within a range of log2 ratio ≤ ±1.5. Thus,
in this study, only changes that showed at least a change of log2
ratio ≥ ±1.5 and a p-value of ≤ 0.01 using a two-sided t-test were
considered signiﬁcant changes in crosslink abundance.
Applying the above criteria to the set of identiﬁed crosslinks
allowed us to probe the relative changes in the crosslinking
patterns of E6AP in the absence and presence of E6 and to
quantify a number of 129 unique linking sites (106 crosslinks and
23 monolinks) over different biological states and replicates
(Supplementary Data 5). Figure 1e shows all 106 crosslinks that
were reproducibly and consistently quantiﬁed (violation= 0; p
value ≤ 0.01 (two-sided t-test); Supplementary Figure 4). Shown
in green are crosslinks that were found to be increased or
upregulated upon binding of E6, while decreased or down-
regulated links are shown in red (deﬁned as a log2 change of ≥
±1.5).
The majority of crosslinks did not substantially change in
abundance (depicted in gray, Fig. 1e), indicating that large areas
of E6AP are unaffected by the presence of E6. However,
crosslinking was markedly altered within two prominent features
that clearly indicate conformational dynamics within E6AP. First,
multiple crosslinks within the HECT binding domain as well as
emanating from it toward the E6 binding region decreased in the
presence of E6 (red, Fig. 1d, e). However, more striking were a
collection of crosslinks between the N- and C-terminal regions of
E6AP that were signiﬁcantly upregulated upon binding of E6, in
some cases exceeding a 100-fold increase in intensity (green,
Fig. 1d, e; Supplementary Data 5, 13, 14). To conﬁrm that these
changes resulted from binding of E6 to E6AP, rather than its mere
presence, we performed equivalent q-XL-MS experiments with
the E6_L50E mutant. As expected, no signiﬁcant up- or
downregulated links were detected (Fig. 1f, Supplementary
Figure 5, Supplementary Data 6, 15, 16). Taken together, our q-
XL-MS data therefore indicates that upon binding, E6 induces a
conformational rearrangement of E6AP that brings the N- and C-
terminal regions into closer proximity.
SILAC-XL-MS reveals weak interactions between E6AP N-
termini. Determination of the crystal structure of the isolated
HECT domain of E6AP revealed that the HECT domain can
assume a homo-trimeric conformation38. While solution binding
experiments and mutational analysis indicated that trimer for-
mation was an artifact of crystal packing38, more recent kinetic
and modeling experiments46,47 suggest that to display E3 ligase
activity, E6AP may have to form homo-trimers. A possible
explanation for these seemingly contradictory results is that oli-
gomeric E6AP-E6AP interactions are transient and too ﬂeeting to
be detected by conventional solution binding assays. In principle,
low afﬁnity protein–protein interactions can be stabilized by
suitable crosslinkers48. However, conventional XL-MS cannot
readily distinguish between intra-subunit crosslinks and inter-
subunit crosslinks between individual protomers within a homo-
oligomer (with the exception of sequence identical peptides that
are bijective within the particular protein sequence). While it has
been shown that homodimeric complexes can in principle be
reconstituted from mixtures of 14N/15N-labeled subunits49–52,
this approach is not readily extensible to larger complexes. To
address this shortcoming, we combined XL-MS with stable iso-
tope labeling with amino acids in cell culture (SILAC)53.
We ﬁrst tested and validated our SILAC-XL-MS workﬂow
using the known homodimer Glutathione S-transferase (GST)
from Schistosoma japonicum. We expressed GST in an E. coli
strain that is auxotrophic for lysine and arginine54 using minimal
media supplemented with either light lysine/arginine or heavy
isotope-labeled lysine (D4; K+ 4.025108 Da)/arginine (13C6 &
15N4: R+ 10.00826 Da). “Heavy” and “light” GST were puriﬁed
separately. Subsequently, the resulting protein preparations were
crosslinked and analyzed using an adapted version of the xQuest
software suite (Methods). We then compared the pattern of links
after crosslinking either light GST alone (Supplementary Data 7),
or a mixture of light and heavy GST (Supplementary Data 8). As
expected, “heavy” peptides were only identiﬁed in samples
containing heavy GST (Supplementary Figure 6A). Crosslinks
between “light” and “heavy” peptides clustered to lysines close to
the dimer interface, with the highest scoring peptide bridging
lysines K10 and K124, which align at the dimer border
(Supplementary Figure 6B). Having validated our approach for
analyzing oligomeric contacts by XL-MS and SILAC with a
known dimer, we next analyzed E6AP using the same approach.
Control experiments conﬁrmed that SILAC labeling of E6AP had
no inﬂuence on its E3 activity (Supplementary Figure 6C). “Light”
and “heavy” E6AP preparations were mixed in a 1:1 ratio. As
E6AP oligomers are not stable under the conditions used for
puriﬁcation (Supplementary Figure 6D and Methods), this should
result in the formation of mixed oligomers consisting of “light”
and “heavy” E6AP molecules, assuming E6AP oligomers exist.
Homomeric interlinks within E6AP detected by SILAC-XL-MS
are shown in Fig. 2 in the absence (Fig. 2a) and presence of E6
(Fig. 2b). Here, we identiﬁed 109 unique lysine–lysine contact
sites (uxIDs) within full-length E6AP in the absence of E6,
corresponding to 379 unique crosslinks (containing 204
light–light, 168 heavy–heavy, and 7 light–heavy links) that were
identiﬁed in total over three biological replicates (Supplementary
Data 9). In the presence of E6, we identiﬁed 108 unique
lysine–lysine contact sites (uxIDs) within full-length E6AP,
corresponding to 383 unique crosslinks (containing 204
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Fig. 2 SILAC-XL-MS reveals weak interactions between E6AP N-termini.
Identiﬁed interlinks between two E6AP protomers (i.e., heavy and light
version of E6AP). Shown are the interlinks in the absence (a) and presence
of E6 (b)
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light–light, 172 heavy–heavy, and 7 light–heavy links) (Supple-
mentary Data 10). Comparison of the two patterns of light–heavy
interlinking indicates that E6 does not signiﬁcantly alter E6AP
oligomerization, as suggested previously46. The identiﬁed homo-
dimeric links are located in the N-terminal part of E6AP, i.e., the
N-termini interact with each other in the establishment of the
E6AP homo(di)mer, even though the relatively low number of
identiﬁed interlinks cautions us to make an unambiguous
assignment in terms of binding sites within the E6AP homo(di)
mer. However, it is interesting to note that none of the detected
interlinks is located within the C-terminal half of E6AP
comprising the HECT domain, where the oligomerization site
has been previously proposed to be located46,47. In summary,
while the absence of crosslinks does not unambiguously prove
that there is no interaction, our SILAC-XL-MS data suggest that
E6AP can engage in homo-oligomeric interactions, but these are
likely not mediated through the HECT domain, and that
oligomerization is not initiated or intensiﬁed by E6.
E6 contacts the HECT domain of E6AP. We previously
demonstrated that XL-MS can be used to predict and identify
protein–protein interaction sites with high precision55. We
therefore had a closer look at the identiﬁed crosslinks between
E6AP and E6 (Fig. 3a, b). Up to now, a major part of E6AP has
resisted structural analysis. This region spans residues 60-500
(numbering according to human E6AP isoform 133) and is pre-
dicted to be mostly folded, except for two small intrinsically
unfolded stretches comprising residues 100–150 and 370–400,
which contain or are adjacent to the interaction regions for the E3
ligase HERC2 and E6, respectively35,56. Nonetheless, the majority
of identiﬁed interlinks between E6AP and E6 are located within
the three regions of E6AP that could be resolved at high resolu-
tion (Fig. 3b, Supplementary Data 2). One of these links,
E6AP_K350 – E6_K94, conﬁrms the known E6 binding site, as it
links E6 with the lysine that is closest to the small part of the
central region of E6AP (residues 380–394) encompassing the
helical LQELL motif, which is bound to E6 in the crystal
structure40,41,56. Some identiﬁed crosslinks fall within the very N-
terminal region (residues 1–64) which contains a zinc-binding
module termed AZUL domain and whose structure has been
solved by NMR39; however, as we identify crosslinks to K7 of
E6AP in all experiments, this interaction should be regarded with
a certain amount of reservation, as it might be caused by the very
ﬂexible and reactive nature of this particular lysine residue.
Remarkably, most of the identiﬁed interlinks fall within the C-
terminal region (residues 495–852) of E6AP that comprises the
HECT domain, the structure of which has been solved by X-ray
crystallography38. Altogether, we were able to detect 4 unique
uxID crosslinking sites between E6AP and E6 with a total of 10
unique crosslinks (and a total of 127 unique crosslinks including
intralinks) within the HECT domain of E6AP. Intriguingly, all of
the interlinks are located around or very near the catalytically
active cysteine in E6AP at position C82011. These crosslinks
connect the HECT domain of E6AP directly with the two
homologous zinc-binding domains in E6, which themselves adopt
an α–β fold connected by a linker helix40,41.
The richness of the crosslinking data allowed us to model this
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Fig. 3 E6 contacts the HECT domain of E6AP. a Shown are the identiﬁed interlinks between E6AP and E6. Lysine residues and regions of known functions
within E6AP and E6 are color-coded as in Fig. 1. b List with identiﬁed interlinks between E6AP and E6. Numbering is according to human E6AP isoform 133.
Links which can be mapped to existing PDB structures (4XR8; 1C4Z) are highlighted. c Structural model of the binding interface between the HECT domain
of E6AP and E6. The localization densities of the HECT domain of E6AP (residues 495–846) and E6 (residues 1–151) are shown in sand yellow and light
green, respectively, with a single representative ribbon structure embedded. For clarity, UbcH7, a cognate E2 of E6AP, was also added and is shown in
yellow (PDB: 1C4Z). Detected interlinks between E6 and E6AP that map to PDB structures 4XR8 and 1C4Z, respectively, are highlighted in orange. The
catalytic cysteine on position C820 in the HECT domain of E6AP is shown as a red ball. The model is shown from the top (left) and from a side view (right)
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guided integrative structural modeling57,58. Using the crosslinking
dataset (Supplementary Data 2) and the high-resolution structures
of the HECT domain of E6AP (PDB: 1C4Z) and of E6 (PDB: 4XR8)
as an input for our modeling approach (see Methods), we derived an
unbiased, highly reproducible and robust model for the E6AP–E6
binding interface, where the sampling runs converged onto one
main cluster of structural solutions (Supplementary Figure 7). The
average precision for the E6 main cluster was ~6 Å, while E6AP was
used as reference to align to, using a root-mean-square deviation
(rmsd) cutoff for clustering of 5 Å (Supplementary Figure 7).
In this model, E6 is ﬁrmly placed next to the catalytic center of
the HECT domain and adjacent to the known E2 binding site (for
clarity, the cognate E2 of E6AP, UbcH7, was added38) (Fig. 3c).
Our crosslinking data together with the crosslinking-based
modeling therefore identify a E6AP–E6 binding site that is in
direct vicinity to the catalytic center of the HECT domain and
does not overlap with the known E2 binding site38. This indicates
that the HECT domain can simultaneously interact with E6 and
cognate E2s, thereby ensuring efﬁcient ubiquitylation of substrate
proteins.
Distinctive binding sites within the E6AP–E6–p53 complex.
Besides the interaction with E6 and cognate E2s, it can be pos-
tulated that the HECT domain of E6AP also comes into close
proximity to substrate proteins for subsequent ubiquitylation.
The tumor suppressor p53 is the best characterized substrate of
the E6–E6AP complex14–16. Thus, we included puriﬁed recom-
binant p53 (Supplementary Figure 9) to assemble the
E6AP–E6–p53 enzyme–substrate complex. Following cross-
linking with DSS, we were able to identify 105 unique
lysine–lysine contact sites, corresponding to 305 unique cross-
links that were identiﬁed in total over three biological replicates
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Fig. 4 Distinctive binding sites within the E6AP–E6–p53 complex. a Shown are the identiﬁed interlinks between E6AP, E6, and p53. Lysine residues and
regions of known functions within E6AP and E6 are color-coded as in Fig. 1. Functional domains in p53—transactivation domain, DNA binding domain,
oligomerization domain and regulatory region—are shown in signal white, gray white, telegrey, and white aluminum, respectively. Crosslinks between
sequence identical peptides that are bijective within the particular protein sequence are shown as red loops. b List with identiﬁed interlinks between p53,
E6AP, and E6. Numbering is according to human E6AP isoform 133. Links which can be mapped to existing PDB structures (4XR8; 1C4Z) are highlighted. c
Structural model of the binding interface between the HECT domain of E6AP, E6, and p53. The localization densities of the HECT domain of E6AP (residues
495–846), E6 (residues 1–151), and p53 (residues 94–292) are shown in sand yellow, light green, and telegrey, respectively, with a single representative
ribbon structure embedded. For clarity, UbcH7, a cognate E2 of E6AP was also added and is shown in yellow (PDB: 1C4Z). Detected interlinks between E6,
p53, and E6AP that map to PDB structures 4XR8 and 1C4Z, respectively, are highlighted in orange. The catalytic cysteine at position C820 in the HECT
domain of E6AP is shown as a red ball. Residue K292 of p53 (most C-terminal lysine residue in the model) is shown as a gray ball. The model is shown
from a side view (left), using the exact same view as in Fig. 3 right panel, and rotated around its axis (right)
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We identify several links that ﬁrmly connect the DNA binding
region of p53 with the HECT domain of E6AP and also with the
N-terminal zinc ﬁnger in E6. There is also an additional crosslink
between the HECT domain of E6AP and the C-terminal 30
amino acids of p53 (E6AP_K799 - p53_K373) (Fig. 4a, b;
Supplementary Data 11). Concerning the interaction of E6 with
E6AP, the links not only contained the one close to the helical
LQELL E6 binding motif but also the majority of the crosslinks
between E6 and the HECT domain identiﬁed above in the
experiments to Fig. 3a, b (Fig. 4a). In fact, looking at the picture
that emerges from the entirety of identiﬁed E6AP–E6 interlinks,
the crosslinking pattern between E6AP and E6 in the presence of
p53 almost exactly corresponds to the one in the absence of p53,
indicating that the identiﬁed binding pattern between E6AP and
E6 is also relevant during the formation of the enzyme–substrate
complex (Fig. 4a, b; Supplementary Data 11). Moreover, the same
two lysine residues that are located within the HECT domain of
E6AP and which make up half of the unique crosslinking sites
between E6AP and E6 are also involved in crosslinks formed
between p53 and E6AP. This indicates that within the
E6AP–E6–p53 enzyme–substrate complex, E6 and p53 are
positioned next to each other and in close proximity to the
catalytic center of the HECT domain.
Applying crosslinking guided integrative modeling corrobo-
rates these ﬁndings. Using the crosslinking dataset from the
E6AP–E6–p53 complex (Supplementary Data 11) and including
E6 and p53 into a single rigid body41 in order to enforce the
established interface between the two proteins leads again to a
highly reproducible and robust model, where sampling runs
converged onto one main cluster (Supplementary Figure 7). For
the E6AP–E6–p53 complex, the average precision for the main
cluster was ~7 Å for p53 and ~5 Å for E6, while E6AP was again
used as reference to align to with an rmsd cutoff for clustering of
5 Å (Supplementary Figure 7). Comparing this model to our
model on the E6AP–E6 alone dataset and using the same view as
in Fig. 3c (right panel) shows that the E6AP–E6 binding interface
between E6AP and E6 is very similar (Fig. 4c, left panel). In our
model of the E6AP–E6–p53 interface, E6 is ﬁrmly placed next to
the catalytic center of the HECT domain and adjacent to the E2
binding site (for clarity, UbcH7 was also added). Here, p53 is
located adjacent to E6 and the catalytic center of E6AP (Fig. 4c,
left panel). Rotating the model around its axis highlights the
distance between the potential ubiquitylation sites within the
DNA binding domain of p5359 and the catalytic cysteine residue
of E6AP (Fig. 4c, right panel).
In conclusion, our crosslinking data together with the
crosslinking-based modeling conﬁrms that the previously unde-
scribed E6AP–E6 binding site is also formed in the presence of a
substrate (i.e., p53) and strongly indicates that both E6 and the
substrate p53 are located in direct vicinity to the catalytic center
of E6AP within the enzyme–substrate complex.
Discussion
This study presents a set of experiments where different
approaches in structural mass spectrometry were applied in order
to obtain insight into how (i) the E6 oncoprotein of cancer-
associated HPVs stimulates the E3 ligase activity of E6AP, and (ii)
E6AP, E6, and the tumor suppressor p53 are structurally and
functionally arranged within the E6AP–E6–p53
enzyme–substrate complex. It also highlights an innovative
approach to study structural aspects and dynamics of
protein–protein interactions within E3 ligase-substrate com-
plexes, in particular when using full-length proteins.
In a ﬁrst set of experiments, crosslinking of E6AP in the
absence and presence of the HPV-16 E6 oncoprotein revealed
distinctive crosslink patterns, which suggested that E6AP
undergoes a structural rearrangement upon binding of E6. This
ﬁnding is in line with recent data, where we showed that in
addition to affecting the substrate spectrum of E6AP, the E6
oncoprotein is a potent activator of E6AP37. While this indicated
that E6AP can adopt high and low activity conformations,
structural evidence for this hypothesis was lacking prior to this
study. Using q-XL-MS and our developed data analysis workﬂow
that allows to normalize the data and exclude potential inﬂuences
on the crosslinking behavior not caused by conformational
dynamics of the protein complex itself, we obtained evidence that
binding of the E6 oncoprotein induces a conformational rear-
rangement within E6AP that brings the N- and C-terminal
regions into closer proximity and/or stabilizes interactions
between these regions. This ﬁnding strongly supports the con-
clusion derived from biochemical analyses that the N-terminal
region of E6AP plays an important role in E6AP-mediated ubi-
quitin chain formation37.
The isolated HECT domain of E6AP can homo-trimerize in
the context of a crystal lattice38 but the functional relevance of
this oligomerization is not clear. However, recent kinetic and
modeling experiments46,47 suggest that in order to function as an
E3 ligase, E6AP may have to form homo-trimers. To resolve these
ambiguities, and to test for possible low afﬁnity interactions
between different E6AP molecules that are not readily detected by
conventional means, we used XL-MS in combination with SILAC.
Data obtained by this approach, which we termed SILAC-XL-MS,
indicate that E6AP is capable of engaging in homo-oligomeric
contacts. However, these interactions are not mediated via the
HECT domain and do not appear to be initiated or intensiﬁed by
the E6 oncoprotein, as suggested previously46,47. While it cannot
be excluded that the GST E6 fusion protein used in this study
was, at least in part, oligomeric, this also clearly indicates that the
oligomerization status of E6 does not affect the oligomerization
behavior of E6AP. To obtain further insight into the potential
oligomerization behavior of E6AP, it will be important to com-
pare the crosslinking pattern of the isolated N-terminal region of
E6AP (i.e., a truncation mutant of E6AP devoid of the HECT
domain), the isolated HECT domain, and full-length E6AP. We
also noticed that the number of uxIDs are lower in experiments,
where SILAC was used in combination with crosslinking. This
may be explained by a direct effect of SILAC on the efﬁciency of
crosslink identiﬁcation. However, as the number of overall
identiﬁed unique crosslinks are roughly similar in SILAC and
non-SILAC crosslinking experiments, this effect may alternatively
be explained by the relative smaller amount of peptides that was
loaded on the column (i.e., the same total peptide amount loaded
onto the LC MS/MS column should translate to half the amount
of light E6AP peptides being present in the SILAC vs the non-
SILAC sample).
Next, we used XL-MS and integrative modeling to probe
protein–protein contact sites between E6AP and the E6 onco-
protein. In doing so, we not only conﬁrmed the known interac-
tion site between E6AP and E640,41,56, but more importantly,
identiﬁed an additional E6AP–E6 binding interface that is in
direct vicinity to the catalytic cysteine residue of the HECT
domain and does not overlap with the known E2 binding site38.
This could in principle be explained by two E6AP binding sites on
one E6 molecule or by binding of two E6 molecules to one E6AP
molecule. Although we cannot distinguish between these possi-
bilities directly, the crosslinks identiﬁed clearly show that two
different regions of E6 are involved in the interaction with the
known E6 binding site and with the HECT domain. It is therefore
likely that one E6 molecule interacts with one E6AP molecule.
This suggests the exciting possibility that upon binding, the E6
oncoprotein not only induces a conformational change in E6AP
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but in addition, may function as a cofactor in E6AP-catalyzed
isopeptide bond formation.
In a last set of experiments, we used XL-MS and integrative
modeling to probe protein–protein contact sites between E6AP,
the E6 oncoprotein, and their substrate p53. Here, we identiﬁed
several interlinks between the HECT domain of E6AP and the
DNA binding region as well as the C-terminal 30 amino acids of
p53. Since the same lysine residues within the HECT domain are
part of crosslinks that are formed between E6AP and E6 and
crosslinks that are formed between p53 and E6AP, our data
strongly suggest that both E6 and p53 are simultaneously in
contact with the HECT domain and in close proximity to its
catalytic center within the E6AP–E6–p53 enzyme–substrate
complex. As MS is an ensemble technology, it is fully conceivable
that the HECT domain within the E6AP–E6–p53
enzyme–substrate complex in the one case forms a crosslink with
the neighboring E6 oncoprotein and in another with the adjacent
p53 molecule. In this context, it is important to note that p53
forms a tetramer and this is presumably also the form of p53 that
was present within the E6AP–E6–p53 complex investigated in
this study, as indicated by the multiple identiﬁed crosslinks (red
loops) between sequence identical peptides in p53 (Fig. 4a). This
is also in line with previous XL-MS studies of p53 alone, which
identiﬁed intralinks and interlinks between different p53 mole-
cules that were all located within the oligomerization domain and
the C-terminal 30 amino acids of p5352. In our study, we could
not only identify several of those links, but detected a signiﬁcantly
larger amount of crosslinks that connect the DNA binding region
with the C-terminal 30 amino acids of p53. We therefore cannot
discriminate by XL-MS for a given crosslink between E6AP and
p53, with which of the p53 subunits of the proposed tetramer it
interacts. This (p53 tetramer) may explain why in our model, the
distance between the catalytic center of E6AP and the nearest
potential ubiquitylation site (K292) in the modeled p53 (i.e. DNA
binding domain) is still ~12 Å (assuming 5 Å and 3 Å ﬂexibility
for a lysine or cysteine residue, respectively), a distance too large
for a nucleophilic attack (i.e., transfer of ubiquitin from the
cysteine residue of E6AP to the lysine residue of p53). Moreover,
there is an additional crosslink between the HECT domain of
E6AP and the C-terminal 30 amino acids of p53 (E6AP_K799 -
p53_K373). As this region of p53 was not included in our
modeling runs, as it is predicted to be disordered, it is possible
that lysine residues within this region of p53 are even closer to the
catalytic center of E6AP than K292. Alternatively, it can be
envisioned that the conformational rearrangement within E6AP
that is induced by E6 binding (vide supra) may also result in a
slight conformational rearrangement within the HECT domain
itself, which would bring the catalytic center into the required
distance for the transfer of ubiquitin onto p53. Furthermore, a
similar rearrangement of the HECT domain may occur, when
ubiquitin is bound to the catalytic cysteine residue via a thioester
bond.
To address the latter possibility, it would be necessary to
generate an E6AP population that is loaded with ubiquitin but in
such a way that ubiquitin cannot be transferred from E6AP onto
p53. Although this may in principle be possible (e.g., by exchange
of the catalytic cysteine residue by a lysine residue60), it is a rather
challenging task to generate amounts sufﬁcient for XL-MS.
Nonetheless, our crosslinking data together with the crosslinking-
based modeling conﬁrms that the previously undescribed
E6AP–E6 binding site is also formed in the presence of a sub-
strate (i.e., p53) and strongly indicates that both E6 and p53 are
located in direct vicinity to the catalytic center of E6AP within the
enzyme–substrate complex.
Our structural understanding of the role of E6AP in
E6–E6AP-p53 complex formation and in E6-mediated ubiqui-
tylation of p53 was so far limited to a 12-amino-acid peptide
derived from E6AP41. It was shown that E6, once bound to the
LQELL motif of E6AP, exposes on its surface a large cleft that
interacts with the p53 DNA binding domain (residues 94–292).
Yet, while revealing the role of the E6-binding region of E6AP
in assembling the E6–p53 interaction, the structure did not
provide any insight into how full-length E6AP is oriented
toward E6 and p53 in the E6AP–E6–p53 complex and how the
E3 activity of E6AP becomes stimulated by interaction with E6.
Our approach did not only reveal distinctive binding sites
within the E6AP–E6–p53 enzyme–substrate complex, but also
put us into the position to propose a model, by which the E3
activity of E6AP is activated in order to transfer ubiquitin onto
its substrates (Fig. 5). Upon binding, E6 induces a conforma-
tional rearrangement in E6AP that brings the AZUL domain
closer to the HECT domain, such allowing the concomitant
positioning of E6 and the substrate p53 into the direct vicinity
of the catalytic center of E6AP. There, E6 functions as an
adaptor, and possibly as an enzymatic cofactor (see above),
facilitating the direct transfer of ubiquitin to p53.
In summary, by structural mass spectrometry we attained
structural and functional insights into the dynamics of the full-
length E6AP–E6–p53 enzyme–substrate complex, paving the way
for a general understanding of how E6AP activity is controlled







AZUL domain HERC2 binding
E6 binding HECT domain
Fig. 5 Model of E6-mediated ubiquitylation of p53. Model of E6-mediated ubiquitylation of p53 in the E6AP–E6–p53 enzyme–substrate complex. Upon
binding, E6 induces a conformational rearrangement in E6AP that brings the AZUL domain closer to the HECT domain. This leads to the concomitant
positioning of E6 and the substrate p53 into the direct vicinity of the catalytic center of E6AP within the enzyme–substrate complex. There, E6 now
functions as an adaptor facilitating the direct transfer of ubiquitin from the HECT domain of E6AP to p53
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Methods
Protein expression and puriﬁcation. His-tagged human E1 enzyme (UBA1) was
expressed in E. coli BL21 DE3 and puriﬁed via Ni-NTA afﬁnity chromatography61.
The hydrophobic patch ubiquitin mutant UbLIA was expressed in E. coli BL21 DE3
and puriﬁed by size exclusion chromatography35. His-tagged UbcH5b was
expressed in E. coli BL21 DE3 and puriﬁed via Ni-NTA afﬁnity chromatography37.
Fractions containing UbcH5b were pooled, dialyzed against 25 mM Tris-HCl pH
7.5, 50 mM NaCl, 1 mM DTT, and stored at −80 °C.
His-tagged E6AP was expressed in E. coli Rosetta DE3 at 20 °C overnight. Cell
pellets derived from 1 L bacterial culture were resuspended in 30 mL of 25 mM
Tris-HCl pH 7.5, 50 mM NaCl, 0.1% Triton, 1 mM DTT, 1 µg/mL aprotinin and
leupeptin, and 100 μM Pefabloc. After sonication and centrifugation (15,000 × g, 4 °
C, 15 min), the supernatant was loaded onto a Ni-NTA afﬁnity chromatography
column (HisTrapTM FF crude, 5 mL column), washed with 8 column volumes of
buffer A (25 mM Tris-HCl pH 7.5, 50 mM NaCl, 1 mM DTT) followed by a
gradient of 20 column volumes to 100% buffer B (25 mM Tris-HCl, 50 mM NaCl,
500 mM imidazole, pH 7.5). Fractions containing E6AP were pooled and subjected
to a second puriﬁcation step by anion exchange chromatography (HiTrapTM Q
HP, 1 mL column), using a gradient from 0 to 50% buffer B in 20 column volumes
(buffer A: 25 mM Tris-HCl pH 7.5, 50 mM NaCl, 1 mM DTT; buffer B: 25 mM
Tris-HCl pH 7.5, 1 M NaCl, 1 mM DTT). 4 mL Amicon ﬁlter devices with a cutoff
of 10 kDa were used for buffer exchange to 25 mM Tris-HCl pH 7.5, 50 mM NaCl,
1 mM DTT and to concentrate the sample. Note that E6AP eluted at ~320–340
mM NaCl, a condition that was also used for size exclusion chromatography
(Supplementary Figure 6).
For SILAC, an E. coli strain auxotrophic for arginine and lysine54 was used to
incorporate 4,4,5,5-deuterated lysine (K+ 4.025108 Da) and 13C6/15N4-labeled
arginine (R+ 10.00826 Da) (Cambridge Isotope Laboratories). Expression was
performed overnight at 20 °C in M9 minimal media (7.52 g/L Na2HPO4, 3 g/L
KH2PO4, 0.5 g/L NaCl, 0.5 g/L NH4Cl) containing 0.4% glucose, 1 mM MgSO4, 0.3
mM CaCl2, 1 µg/L biotin, 1 µg/L thiamine, 134 µM EDTA, 31 µM FeCl3, 6.2 µM
ZnCl2, 0.76 µM CuCl2, 0.42 µM CoCl2, 1.62 µM H3BO3, 81 nM MnCl2. For SILAC-
XL-MS validation experiments, we expressed isotope-labeled GST using the vector
pGEX6P1. Bacterial pellets were lysed using sonication in buffer containing 30 mM
HEPES pH 7.5, 500 mM NaCl, 2 mM DTT, 0.5 mM EDTA, and 1 mM
benzamidine. GST was puriﬁed by batch afﬁnity to glutathione sepharose 4B (GE
Healthcare) and size exclusion using a Superdex 200 column in 20 mM Na Hepes
pH 7.5, 200 mM NaCl. Unlabeled GST was puriﬁed in the same way following
expression in LB media. Following puriﬁcation, both unlabeled and isotope-labeled
GST dimers were dissociated by supplementing the buffer with 6 M urea to induce
dimer dissociation62. Dissociated labeled and isotope-labeled monomers were then
recombined, and urea was removed by serial dilution to enable formation of mixed
unlabeled-isotope-labeled dimers. To conﬁrm that treatment with urea did not
affect the conformation of dimeric GST, we performed XL-MS also with untreated
light GST. The crosslinking patterns for untreated GST (Supplementary Data 12),
and GST subjected to urea unfolding/refolding (Supplementary Data 7), are highly
similar. We also performed control experiments with light GST alone to test the
accuracy of isotope-labeled peptide assignment.
Puriﬁcation of isotope-labeled E6AP was performed as described above for
unlabeled E6AP. As oligomeric E6AP interactions are transient under the
conditions used for puriﬁcation (Supplementary Figure 6D), there was no need to
dissociate light–light and heavy–heavy E6AP dimers prior to cross-linking. GST-
fusion proteins of wild-type HPV-16 E612 and the E6_L50E mutant40 were
expressed in E.coli BL21-CodonPlus-RIL at 37 °C for 4 h. Pellets derived from 1 L
bacterial culture were resuspended in 30 mL PBS, 0.1% Triton, 1 mM DTT and
sonicated, and the lysate cleared by centrifugation (16,000 × g, 4 °C, 15 min). The
supernatant was incubated with 150 µL glutathione-sepharose 4B (GE Healthcare)
at 4 °C for 1 h. Beads were spun down and washed three times with 1 mL PBS.
GST-E6 fusion proteins were eluted four times with 400 µL 25 mM Tris-HCl pH
8.0, 50 mM NaCl, 25 mM gluthatione. 4 mL amicon ﬁlter devices with a cutoff of
10 kDa were used for buffer exchange to 25 mM Tris pH 7.5, 50 mM NaCl, 1 mM
DTT and to concentrate the sample.
His-lipoyl domain-tagged p53 was expressed in E. coli BL21 DE3 at 24 °C
overnight63. Cells were lysed in 50 mM phosphate buffer pH 8.0, 300 mM NaCl,
0.01% NP-40, 1 µg/mL aprotinin and leupeptin, 100 µM Pefabloc, 10 mM DTT.
After sonication the lysate was centrifuged for 20 min at 15,000 × g and the
supernatant was loaded onto a Ni-NTA column. His-tagged p53 was eluted with a
gradient of 25 column volumes from buffer A (50 mM phosphate buffer pH 8, 150
mM NaCl, 0.01% NP-40, 2 mM DTT, 25 mM imidazole) to 100% buffer B (50 mM
phosphate buffer pH 8, 150 mM NaCl, 0.01% NP-40, 2 mM DTT, 1 M imidazole)
and dialyzed overnight (50 mM phosphate buffer pH 7.2, 150 mM NaCl, 0.01%
NP-40, 2 mM DTT) in the presence of thrombin (Sigma-Aldrich). Cleaved p53 was
separated from the His-tagged lipoyl domain using a heparin column. p53 was
eluted from the heparin column with a gradient over 25 column volumes from
buffer A (50 mM phosphate buffer pH 7.2, 150 mM NaCl, 0.01% NP-40, 2 mM
DTT) to 100% buffer B (50 mM phosphate buffer pH 7.2, 1 M NaCl, 0.01% NP-40,
2 mM DTT).
Ubiquitylation assays. For in vitro ubiquitylation, 150 ng E1, 75 ng UbcH5b, 750
ng E6AP, and 2 µg ubiquitin (bovine, Sigma-Aldrich) or UbLIA were incubated in
25 mM Tris-HCl pH 7.5, 50 mM NaCl, 1 mM DTT, 2 mM MgCl2, 2 mM ATP at
30 °C in a total volume of 30 µL. Reactions were stopped after 90 min or the
indicated time by addition of 7.5 µL 5× sample buffer (312.5 mM Tris-HCl pH 6.8,
10% SDS, 500 mM DTT, 0.001% bromphenol blue) and electrophoresed in 12%
SDS-polyacrylamide gels followed by Coomassie blue staining.
Crosslinking coupled to mass spectrometry. Complexes were crosslinked and
measured essentially as described64. In short, ~100 μg of E6AP were crosslinked by
addition of H12/D12 DSS (Creative Molecules) at a ratio of 1.5 nmol/1 µg protein
for 30 min at 37 °C shaking at 650 rpm in a Thermomixer (Eppendorf). In order to
crosslink E6AP in complex, wild-type E6 or the E6_L50E mutant (and p53) were
added in a molar ratio of 1:1(:1) and incubated on ice for 30 min prior to cross-
linking under the same conditions. Proteins were crosslinked directly after pur-
iﬁcation without freezing. After quenching by addition of ammonium bicarbonate
to a ﬁnal concentration of 50 mM, samples were reduced, alkylated, and digested
with trypsin. Digested peptides were separated from the solution and retained by a
solid phase extraction system (SepPak, Waters), and then separated by size
exclusion chromatography prior to liquid chromatography (LC)-MS/MS analysis
on an Orbitrap Fusion Tribrid mass spectrometer (Thermo Scientiﬁc). Data were
searched using xQuest in ion-tag mode with a precursor mass tolerance of 10 ppm.
For matching of fragment ions, tolerances of 0.2 Da for common ions and 0.3 Da
for crosslink ions were applied. Crosslinked samples were prepared in biological
triplicates (i.e., separately expressed and puriﬁed batches of proteins) for all
investigated samples, and each of these was measured with technical duplicates.
Crosslinks were only considered during structural analysis, if they were identiﬁed
in at least two of three biological replicates with deltaS < 0.95 and at least one Id
score ≥25. A list of all identiﬁed links can be found in Supplementary Data 1–16).
Quantitative crosslinking coupled to mass spectrometry. For quantitative
crosslinking coupled to mass spectrometry (q-XL-MS) analysis, the chromato-
graphic peaks of identiﬁed crosslinks between E6AP in the absence and presence of
E6 or E6_L50E were integrated and summed up over different peak groups (taking
different charge states and different unique crosslinked peptides for one unique
crosslinking site into account) for quantiﬁcation by xTract45. Amounts of potential
crosslinks were normalized prior to MS by measuring peptide bond absorption at
215 nm for each fraction. Only high-conﬁdence crosslinks that were identiﬁed
consistently over different biological and technical replicates in a peak group
(xTract settings violations was set to 0) were selected for further quantitative
analysis. Changes in crosslinking abundance are expressed as log2 ratio (e.g.,
abundance state 1, E6AP with E6 was quantiﬁed versus abundance state 2, E6AP
alone). The p value using a two-sided t-test indicates the regression between the
two conditions.
The question of how to assess the signiﬁcance of a measured quantitative
change in a crosslink in terms of relevance for a potential conformational change
on the protein level has to the best of our knowledge not been addressed so far in
the crosslinking ﬁeld; contrary to the sheer reproducibility or statistical validity of a
measured crosslinking change, for which different statistical evaluation criteria
have been proposed. Thus, in order to normalize the data and to identify the subset
of signiﬁcantly changed crosslinks, the quantitative distribution of monolinks
within E6AP in the absence and presence of E6 or E6_L50E was plotted (see Fig. 1d
and Supplementary Figure 5), reasoning that monolink formation is dictated
primarily by accessibility and its local environment (e.g., surrounding amino acid
composition, secondary structure etc.) and therefore only on rare occasions
inﬂuenced by conformational dynamics. Doing this, we identiﬁed the vast majority
of changes in monolink abundances ﬂuctuating within a range of log2 ratio ≤ ±1.5.
Thus, in this study, only changes that showed at least a change of log2 ratio ≥ ±1.5
and a p-value of ≤0.01 for the E6 or ≤0.05 for the E6_L50E dataset were considered
signiﬁcant changes in abundances and are shown in green and red in the 2D
visualizations (Fig. 1d–f; Supplementary Figure 5), respectively. All other changes
were considered insigniﬁcant and are shown in gray.
SILAC-based crosslinking coupled to mass spectrometry. In order to distin-
guish between intralinks within a protomer and interlinks between protomers of a
homomeric interaction, we incorporated the use of stable heavy isotopes via SILAC
(stable isotope labeling with amino acids in cell culture)53 into our XL-MS
workﬂow, which we termed SILAC-based crosslinking coupled to mass spectro-
metry or SILAC-XL-MS. For SILAC-XL-MS, unlabeled GST or E6AP and GST or
E6AP expressed in the presence of stable heavy isotopes are mixed in order to form
hetero-oligomers of unlabeled and isotope-labeled proteins, which are crosslinked
and after MS measurement analyzed by a modiﬁed version of our xQuest analysis
platform. In short, GST or E6AP were expressed in an E. coli strain that is aux-
otrophic for lysine and arginine54 in the absence or presence of stable heavy
isotopes (lysine (D4; K+ 4.025108 Da) and arginine (13C6 & 15N4: R+ 10.00826
Da)), as described above (Protein expression and puriﬁcation). Upon expression
and puriﬁcation, the two GST/E6AP preparations were mixed in a 1:1 ratio (prior
to mixing, GST preparations were treated with 6 M urea to induce dissociation of
light–light and heavy–heavy dimers, see above), and the samples were subsequently
crosslinked and measured on an Orbitrap Fusion Tribrid mass spectrometer.
Subsequently, the data was searched by an adapted version of xQuest. XQuest was
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adapted in a way that it contained two additional artiﬁcial amino acids (B= K+
4.025108 Da and U= R+ 10.00826 Da), an additional crosslinking site (B), and an
artiﬁcial enzyme that cuts at K|R|B|U to allow for an in silico tryptic digestion.
Visualization of crosslinks. Visualization of intra- and interlinks was performed
by xiNET65 using additional in-house scripts for the analysis and representation of
quantitative crosslink information. For the static datasets all links that passed the
evaluation criteria—Id scores > 25 in at least 1 biological replicate, a deltaS value <
0.95 and detection in at least two out of the three independent biological replicates
—are shown. For the differential (quantitative) datasets in Fig. 1d–f and Supple-
mentary Figure 5, only links that were consistently quantiﬁed in all biological
datasets (violation 0) were shown.
Integrative structural modeling. We used the Integrative Modeling Platform
(IMP)57 for modeling the structure of the HECT domain of E6AP and E6 with and
without p53. The approach using crosslinks as restraints in a Bayesian scoring
scheme is described in detail in ref. 58. Accordingly, there are four main steps: (1)
gathering of data, (2) representation of subunits and translation of the crosslinking
data and the prior knowledge into a Bayesian scoring function, (3) conﬁgurational
sampling to produce an ensemble of models that minimize the Bayesian scoring
function, and (4) analysis of the ensemble. IMP allows for coarse-grained model-
ing, i.e. the inclusion of different resolution levels into a model. Different resolution
levels are represented by accordingly sized beads (spheres) in a modeling run.
In the Bayesian scoring scheme models are ranked according to their likelihood
and prior probability. The score is the negative logarithm of their product. The
likelihood contains the crosslinking data, while the priors contain information
about sequence connectivity in protein chains as well as excluded volume between
all pairs of beads. The likelihood is deﬁned through a forward model, which
quantiﬁes the probability of the formation of a crosslink given the distance between
two residues in the model, as well as a noise model, which weighs the deviation
between observed crosslinks and the forward model.
For our modeling runs, we employed the known crystal structures of the HECT
domain of E6AP (PDB ID: 1c4z) and E6/p53 (PDB ID: 4xr8). In the modeling runs,
the following residues were represented by beads (one residue per bead) and
constrained into rigid bodies: for E6AP residues 495–846 of chain A, for E6
residues 1–151 of chain F and for p53 residues 94–292 of chain C. Residues
144–151 of E6 in chain C are not represented in the crystal structure and were
grouped into a single ﬂexible bead. E6 and p53 were included into a single rigid
body in order to enforce the established interface between the two proteins. The
crosslink input databases for the modeling included all links (until ld-20) which
were found in at least two out the three biological replicates. From each replicate
the highest scoring link was chosen.
The actual models were computed by Replica Exchange Gibbs sampling, based
on Metropolis Monte Carlo sampling66. The Monte Carlo movements included
random translation and rotation of rigid bodies with a maximum of 10 Å and 1
radian, respectively.
The sampling was run on 16 replicas producing 15,000 models each, with
temperatures ranging from 1.0 to 2.5 (technical units). The 25% best scoring
models were saved, leading to 60,000 saved models overall. These replicas were run
in three independent sampling runs with random initial conﬁgurations to assess
convergence and accounting for 180,000 models overall.
The models from all three sampling runs were pooled and the 500 best scoring
models from each sampling run were clustered using the root-mean-square
deviation (rmsd) of E6 and p53 (when p53 was included in the sampling). The
HECT domain of E6AP was used as reference to align to, as its position was ﬁxed
during the sampling. The rmsd cutoff for clustering was 5 Å. The cluster center was
deﬁned as the cluster member whose rmsd with respect to the other members is
minimal. It was used to represent the atomistic coordinates of the system. The
overall precision of each protein was calculated as the mean root-mean-square
ﬂuctuation with respect to the cluster center. Furthermore, to represent the
variance of the solutions, the superposed structures of each cluster were converted
into a localization density67,68.
For each setup (i.e., with and without p53), the sampling runs converged onto
one main cluster. To assess convergence, all replicates were also clustered
independently, resulting in the same main clusters as the pooled clustering. The
average precision for the E6 main cluster in the modeling runs not containing p53
was ~5 Å. In the run containing p53, it was ~8 Å for p53 and ~5 Å for E6.
To assess robustness, the modeling procedure described above was repeated
while randomly removing 15% of the crosslinks (jackkniﬁng). Additionally, we also
repeated the modeling using only crosslinks with ld-scores greater than 30. In both
cases the sampling runs converged onto the same clusters with precisions within 1
Å of the original runs, as can also be seen in the rmsd matrices produced by these
runs (Supplementary Figure 7). Additional modeling runs, in which all interlinks
between E6AP and E6 for a speciﬁc uxID were purposely removed, as well as an
independent modeling approach using HADDOCK conﬁrm the overall robustness
and reproducibility of our modeling results (Supplementary Figure 8).
Code availability. We have compiled a repository of all the required changes to the
xQuest software. The git repository containing all modiﬁed xQuest ﬁles and
instructions on how to install them may be found on github.com (https://github.
com/stengellab/silac_xl_ms).
Data availability
All data generated or analyzed during this study are included in this published
article (and its supplementary information ﬁles). The MS data (raw ﬁles, xQuest
and xTract ﬁles) have been deposited to the ProteomeXchange Consortium via the
PRIDE69 partner repository with the dataset identiﬁer PXD010002. Both the
structural model of the binding interface between the HECT domain of E6AP and
E6 (PDBDEV_00000022) and the structural model of the binding interface
between the HECT domain of E6AP, E6, and p53 (PDBDEV_00000023), including
localization densities, have been deposited in PDB-dev.
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